Promising Potential of Tourmaline Bio’s TOUR006: A Strong Buy Recommendation

Analyst Kostas Biliouris from BMO Capital reiterated a Buy rating on Tourmaline Bio (TRML – Research Report) and keeping the price target at $35.00.

Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the promising potential of Tourmaline Bio’s lead product candidate, TOUR006. The Phase II trial results for TOUR006, also known as Paci, demonstrated an impressive 85% median reduction in hs-CRP levels and an 83% response rate, which are competitive with existing treatments. The infrequent dosing regimen of every three months (Q3M) for Paci could offer a significant advantage over competitors like Zilti, which requires monthly dosing, potentially reducing the treatment burden for patients.
Moreover, the safety profile of Paci is encouraging, with no increased incidence of adverse events compared to placebo, and no cases of neutropenia or thrombocytopenia, which are concerns with other IL-6 receptor-targeting treatments. These factors, combined with the strategic interest that the strong Phase II data is likely to attract, position Tourmaline Bio well in the IL-6 space. The upcoming ZEUS CVOT data could further validate the relationship between IL-6 and ASCVD, potentially enhancing Paci’s profile and market position.

Biliouris covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and Tourmaline Bio. According to TipRanks, Biliouris has an average return of -17.7% and a 26.09% success rate on recommended stocks.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $58.00 price target.